What is Inflammatix?
Inflammatix is a molecular diagnostics company dedicated to transforming patient care through the rapid interpretation of immune system responses. By moving beyond traditional pathogen detection, the company utilizes proprietary biomarkers to provide physicians with actionable insights, facilitating faster and more accurate treatment decisions. This approach is particularly vital in high-stakes clinical environments such as emergency departments and intensive care units, where time-to-diagnosis directly correlates with patient outcomes. The company's integration of sophisticated machine learning algorithms allows for the processing of complex biological data, positioning Inflammatix at the intersection of biotechnology and digital health. Its market position is further bolstered by a history of strategic grants and venture-backed funding, which have supported the transition from research-stage innovation to advanced clinical application.
How much funding has Inflammatix raised?
Inflammatix has raised a total of $216.5M across 6 funding rounds:
Other Financing Round
$6M
Series C
$32M
Grant
$7.4M
Series D
$102M
Grant
$12.1M
Series E
$57M
Other Financing Round (2019): $6M with participation from Biomedical Advanced Research and Development Authority (BARDA)
Series C (2020): $32M led by Khosla Ventures, Northpond Ventures, Grey Sky Venture Partners, and Think.Health Ventures
Grant (2020): $7.4M supported by Biomedical Advanced Research and Development Authority
Series D (2021): $102M featuring OSF Healthcare Ventures, D1 Capital Partners, Northpond Ventures, Khosla Ventures, and Think.Health
Grant (2021): $12.1M backed by Biomedical Advanced Research and Development Authority (BARDA
Series E (2024): $57M with participation from Northpond Ventures, Iberis Capital, Think.Health Ventures, Khosla Ventures, and D1 Capital Partners Master
Key Investors in Inflammatix
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on a broad range of areas including health, AI, and enterprise software.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, supporting breakthrough innovations and entrepreneurial ventures.
D1 Capital Partners Master
D1 Capital Partners Master LP is a New York-based firm operating in the venture capital and private equity industry, focusing on high-growth investment opportunities.
What's next for Inflammatix?
With the successful closure of its latest funding round, Inflammatix is well-positioned to scale its operations and navigate the regulatory pathways required for broader clinical adoption. The strategic focus will likely shift toward commercializing its diagnostic platforms and deepening its footprint in the sepsis management space. By maintaining strong relationships with institutional investors and public health authorities, the company is poised to address the growing demand for rapid, point-of-care diagnostics that reduce the burden on global healthcare systems. Future efforts will likely prioritize the expansion of its biomarker library and the refinement of its diagnostic algorithms to ensure sustained competitive advantage in the rapidly evolving molecular diagnostics landscape.
See full Inflammatix company page
